glp 1 temporary use Study: Many Patients Stop Weight Management Drugs Early GLP-1 use reaches record high
Description
More importantly, we found that the causal effect of ISI on MASLD was independent of BMI, which means the effects of GLP-1R-based agonists on MASLD were partly independent of their weight-loss effect

G.et al (2023)
Efruxifermin combined with a GLP-1 receptor agonist reduces liver fat in NASH

The role of AMPK in macrophage metabolism, function and polarisation

However, when researchers compared these findings to lifestyle-driven interventions, the contrast was striking

Who Can Receive Weight Loss Medications Typically, FDA-approved weight loss medications are available for adults with a BMI of 30 or higher, or a BMI of 27 with a weight-related condition such as diabetes or high blood pressure
